Could Collegium Pharmaceutical, Inc. (COLL) Lose its Strength? The Stock Reaches 52-Week High

January 23, 2018 - By Max Morgan

The stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) hit a new 52-week high and has $26.47 target or 3.00 % above today’s $25.70 share price. The 6 months bullish chart indicates low risk for the $836.85M company. The 1-year high was reported on Jan, 23 by Barchart.com. If the $26.47 price target is reached, the company will be worth $25.11M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 5.67% or $1.38 during the last trading session, reaching $25.7. About 716,373 shares traded. Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has declined 44.24% since January 23, 2017 and is downtrending. It has underperformed by 60.94% the S&P500.

Analysts await Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to report earnings on March, 8. They expect $-0.55 earnings per share, up 46.08 % or $0.47 from last year’s $-1.02 per share. After $-0.45 actual earnings per share reported by Collegium Pharmaceutical, Inc. for the previous quarter, Wall Street now forecasts 22.22 % negative EPS growth.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings Coverage

Among 7 analysts covering Collegium Pharmaceutical Inc (NASDAQ:COLL), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Collegium Pharmaceutical Inc has $35 highest and $1400 lowest target. $23.33’s average target is -9.22% below currents $25.7 stock price. Collegium Pharmaceutical Inc had 15 analyst reports since February 19, 2016 according to SRatingsIntel. On Friday, July 14 the stock rating was maintained by Jefferies with “Buy”. The company was maintained on Thursday, December 7 by Piper Jaffray. The stock has “Buy” rating by Gabelli on Tuesday, September 13. On Thursday, December 14 the stock rating was maintained by Piper Jaffray with “Buy”. Piper Jaffray maintained the shares of COLL in report on Wednesday, November 29 with “Buy” rating. The rating was maintained by Jefferies on Wednesday, August 16 with “Buy”. The stock has “Outperform” rating by William Blair on Friday, February 19. As per Friday, June 9, the company rating was maintained by Janney Capital. The stock has “Buy” rating by Janney Capital on Monday, November 6. Jefferies maintained Collegium Pharmaceutical, Inc. (NASDAQ:COLL) rating on Monday, June 12. Jefferies has “Buy” rating and $1500 target.

More recent Collegium Pharmaceutical, Inc. (NASDAQ:COLL) news were published by: Nasdaq.com which released: “Collegium to Participate in the Guggenheim Securities 5th Annual Boston …” on November 22, 2017. Also Seekingalpha.com published the news titled: “Collegium Pharmaceutical’s (COLL) CEO Mike Heffernan on Q3 2017 Results …” on November 09, 2017. Fool.com‘s news article titled: “Here’s Why Collegium Pharmaceutical Rose as Much as 23.5% Today” with publication date: December 05, 2017 was also an interesting one.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. The company has market cap of $836.85 million. It offers Xtampza, an oral formulation of oxycodone, for the management of pain. It currently has negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: